Pharmaceuticals

With a novel nasal spray targeting the host, not the virus, RA Capital-backed NorthLinks Bio aims to create a broad-spectrum defense against respiratory threats.

Amid crushing industry pressures, McKesson's ideaShare event reveals a strategic blueprint: leveraging AI and advocacy to keep independent pharmacies alive.

Kalaris Therapeutics, backed by VEGF pioneer Dr. Napoleone Ferrara, presents early data on its next-gen eye drug. Can TH103's novel science overcome recent development hurdles?

Right Brain Bio is leveraging Dassault Systèmes' powerful MEDIDATA platform to accelerate a radical new therapy that could reverse Parkinson's pathology.

Zevra Therapeutics' new data for MIPLYFFA in infants with NPC is more than a medical update; it's a key commercial milestone to widen its market.

Amylyx reveals positive initial safety data for its new ALS drug, AMX0114, a critical step as the firm aims to rebuild after the Relyvrio withdrawal.

Soleo Health's repeat URAC award isn't just a corporate win. It signals a crucial shift where data-driven quality becomes the bedrock of a resilient system.

With a promising drug, fresh cash, and a new board member known for billion-dollar exits, Avalo Therapeutics is signaling a major strategic shift.

In a head-to-head battle, Takeda's zasocitinib showed superior skin clearance over a key competitor, signaling a potential new standard for oral therapy.

A new, fast-acting neurotoxin with a two-week lifespan just hit the market. Allergan's Boey® aims to capture hesitant consumers with a low-commitment 'trial run'.

An FDA fast-track for a devastating brain disease drug is a beacon of hope for patients and a major validation of Alphabet's long-term biotech strategy.

A new partnership between AGEPHA Pharma and Close-Up Intl reveals how AI is not just a buzzword, but a critical tool for getting vital medicines to patients.

Nippon Shinyaku and Boston Children's Hospital deepen their pact, combining corporate might with research prowess to create new therapies for rare neurology.

HLS Therapeutics is betting on itself with a larger share buyback. We analyze if this is a signal of deep value or a sign of limited growth opportunities.

Insmed recruits J&J and Novartis veteran Samuele Butera to execute the multi-billion-dollar launch of BRINSUPRI and expand its respiratory franchise.

A biopharma firm's celebrated 20% growth is now alleged to be a mirage, sparking a fraud lawsuit that questions where the line is drawn between ambition and accountability.

A new survey reveals the crippling cost of insulin, forcing millions to choose between medicine and groceries. A bipartisan bill may offer a lifeline.

With millions suffering from chronic gout, Atom Therapeutics' new drug promises more than relief—it aims to reverse damage. Is this the breakthrough?

The European Commission has approved MAVIRET for acute Hepatitis C, a move set to streamline patient care and accelerate progress against a silent epidemic.

AbbVie's blockbuster SKYRIZI wins European approval for pediatric psoriasis, unlocking a new market and offering a new standard of care to young patients.